XXXX . A guide to pharmacological therapy.

@entity12881 @entity1 @entity1033 @entity645
The pharmacological therapy for @entity12881 remains dominated by @entity1033 , although a number of related compounds are currently under investigation. Recommended treatment for @entity12881 is oral @entity1033 200mg 5 times daily for 5 days, with intravenous therapy reserved for complicated episodes. Although topical @entity1033 may be of benefit, no improvement in the systemic symptoms is provided by this formulation. No preparation prevents the onset of recurrent episodes. The management of recurrent episodes is more controversial, with studies of episodic treatment with both topical and oral @entity1033 yielding mixed and at times conflicting results. Episodic treatment with oral @entity1033 initiated early by the @entity1 appears to have the most favourable results, and if initiated at the onset of prodromal symptoms may abort the episode in some @entity1 . In @entity1 with frequent recurrences, suppressive therapy with oral @entity1033 should be considered. A starting dose of 200mg 4 times daily appears to be the most effective, although 400mg twice daily may suffice. The total daily dose should be reduced as far as possible, and treatment should be interrupted on a yearly basis to determine the need for continuing suppression. The management and pharmacological therapy of genital HSV in pregnancy remains controversial and studies of oral @entity1033 in late pregnancy are currently under way. @entity12881 may be particularly severe in the immunocompromised host and suppressive oral @entity1033 should be initiated promptly. HSV resistance to @entity1033 is an increasing problem in such @entity1 , in particular those infected with @entity645 , and may necessitate treatment with intravenous foscarnet.
